UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001013
Receipt number R000001209
Scientific Title Phase I clinical study of tumor-specific vaccine using novel tumor antigen SCRN1-derived HLA*0201 restricted epitope peptide against advanced gastric cancer
Date of disclosure of the study information 2008/02/04
Last modified on 2009/05/26 10:07:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase I clinical study of tumor-specific vaccine using novel tumor antigen SCRN1-derived HLA*0201 restricted epitope peptide against advanced gastric cancer

Acronym

SCRN1 peptide vaccine against gastric cancer

Scientific Title

Phase I clinical study of tumor-specific vaccine using novel tumor antigen SCRN1-derived HLA*0201 restricted epitope peptide against advanced gastric cancer

Scientific Title:Acronym

SCRN1 peptide vaccine against gastric cancer

Region

Japan


Condition

Condition

Advanced gastric cancer

Classification by specialty

Medicine in general Gastroenterology Surgery in general
Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

Phase I clinical study

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase I


Assessment

Primary outcomes

Assessment of safety and antitumor immune responses

Key secondary outcomes

Clinical efficacy


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Vaccine Gene
Maneuver

Interventions/Control_1

peptide vaccine therapy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

Performance status 0-2
HLA-A20201
Refractory to 5FU containing chemotherapeutic regimen

Key exclusion criteria

pregnancy
uncontroled infection
uncontroled cerebral metastasis
etc.

Target sample size

6


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masahisa Jinushi

Organization

Institute of Medical Science, University of Tokyo

Division name

Surgery and Bioengeering

Zip code


Address

4-6-1, Shirokane-dai, Minato-ku

TEL

03-5449-5582

Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

University of Tokyo

Division name

Surgery and Bioengeering

Zip code


Address


TEL

03-5449-5582

Homepage URL


Email

jinushi@ims.u-tokyo.ac.jp


Sponsor or person

Institute

Institute of Medical Science, University of Tokyo

Institute

Department

Personal name



Funding Source

Organization

Goverment

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 02 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2007 Year 12 Month 06 Day

Date of IRB


Anticipated trial start date

2008 Year 01 Month 01 Day

Last follow-up date

2009 Year 03 Month 01 Day

Date of closure to data entry

2009 Year 03 Month 01 Day

Date trial data considered complete

2009 Year 03 Month 01 Day

Date analysis concluded

2009 Year 03 Month 01 Day


Other

Other related information



Management information

Registered date

2008 Year 02 Month 04 Day

Last modified on

2009 Year 05 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001209


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name